Axxess Pharma, Inc. Provides Update Regarding Mina Mar Marketing Group

ONTARIO, CA--(Marketwire - August 12, 2010) - Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, announces on June 14, 2010 Taylor Capitol, Inc was hired as Investor Relations to replace Mina Mar Marketing Group. It is Axxess Pharma’s belief that Mina Mar was not fulfilling their obligations as Investor Relations and was then replaced.

Since being replaced, it has come to the attention of Axxess Pharma that Mina Mar Marketing Group began retaliating against AXXE for a failed relationship that never materialized. Management believes based on negative postings, Mina Mar is endeavoring to damage both the integrity of AXXE and its shareholders. Axxess Pharma is now initiating action to recover damages by or related to Mina Mar Marketing Group.

“Despite the negative connotations by Mina Mar, sales for quarter ending March 31, 2010 increased to $548,000. We remain on track to increase our fiscal year end 2010 sales by 75 percent. This growth will be attributed to our current and growing line of Health Canada approved and soon to be FDA approved prescription and non-prescription drugs. In the coming press releases we will provide more detail of the sales generation of our current and future product lines,” stated Gerald Sequeira, President/CEO.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.